Welcome to RedHill Biopharma Ltd.

RedHill Biopharma (NASDAQ: RDHL; TASE: RDHL) is a biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer and related conditions.

.

The Company’s current product pipeline includes:

.

RHB-104 - A combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway, Multiple Sclerosis (MS), with a Phase IIa proof of concept study currently underway, and Rheumatoid Arthritis, with a planned Phase IIa study.

.

RHB-105 - A combination therapy for Helicobacter pylori infection, with a Phase III study currently underway.

.

RHB-106 - An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.

.

RHB-103 - An oral thin film formulation of rizatriptan, for the treatment of acute migraine, with a U.S. NDA under review by the FDA. RedHill plans to file an MAA in Europe in 2014.

.

RHB-102 - A once-daily oral pill of ondansetron for the prevention of nausea and vomiting.


RHB-101 - A once-daily formulation of carvedilol, for the treatment of congestive heart failure and high blood pressure, planned to be submitted for a U.S. New Drug Application (NDA) and a Marketing Authorization Application (MAA) in Europe.

.

Upcoming Events & Presentations

For 2014 events and conferences, please visit the Investors section